argenx announces results of Annual General Meeting of Shareholders

argenx announces results of

Annual General Meeting of Shareholders

Breda, the Netherlands / Ghent, Belgium

- argenx (Euronext & Nasdaq: ARGX), a clinical-stage biotechnology company developing a deep pipeline of differentiated

antibody-based therapies for the treatment of severe autoimmune diseases and cancer, today announced that the proposed resolutions

presented at our Annual General Meeting of Shareholders were duly passed at the meeting, which was held today at 10:00 a.m. CET.

As part of the approved resolutions:

The Annual General Meeting has furthermore

approved the 2019 remuneration report, although the vote on the new remuneration policy, updated in order to align with the Dutch

Civil Code of December 2019, did not reach the 75% majority required for approval (70% in favour). The current remuneration policy

will therefore remain in effect until the next general meeting.

The results of the votes will be posted

shortly on our website.

All documents relating to the shareholders'

meeting can be consulted on our website: www.argenx.com

argenx is a global immunology company developing

antibody-based medicines for patients suffering from severe autoimmune diseases and cancer. By translating immunology breakthroughs

into innovative drug candidates, argenx is building a world-class portfolio of first-in-class antibodies in both early and late

clinical-stages of development. argenx is evaluating efgartigimod in multiple serious autoimmune indications and cusatuzumab in

hematological malignancies in collaboration with Janssen, along with advancing earlier stage assets within its therapeutic franchises.

For further information, please contact:

Beth DelGiacco, Vice President, Investor Relations

Joke Comijn, Director Corporate Communications & Investor

Forward-looking Statements

The contents of this announcement include

statements that are, or may be deemed to be, "forward-looking statements." These forward-looking statements can be

identified by the use of forward-looking terminology, including the terms "believes," "estimates," "anticipates,"

"expects," "intends," "may," "will," or "should" and include statements

argenx makes concerning its annual meeting and related plans and the intended results of its strategy. By their nature, forward-looking

statements involve risks and uncertainties and readers are cautioned that any such forward-looking statements are not guarantees

of future performance. argenx's actual results may differ materially from those predicted by the forward-looking statements

as a result of various important factors, including argenx's expectations regarding its the inherent uncertainties associated

with competitive developments, preclinical and clinical trial and product development activities and regulatory approval requirements;

argenx's reliance on collaborations with third parties; estimating the commercial potential of argenx's product candidates;

argenx's ability to obtain and maintain protection of intellectual property for its technologies and drugs; argenx's

limited operating history; and argenx's ability to obtain additional funding for operations and to complete the development

and commercialization of its product candidates. A further list and description of these risks, uncertainties and other risks can

be found in argenx's U.S. Securities and Exchange Commission (SEC) filings and reports, including in argenx's most

recent annual report on Form 20-F filed with the SEC as well as subsequent filings and reports filed by argenx with the SEC. Given

these uncertainties, the reader is advised not to place any undue reliance on such forward-looking statements. These forward-looking

statements speak only as of the date of publication of this document. argenx undertakes no obligation to publicly update or revise

the information in this press release, including any forward-looking statements, except as may be required by law.